Loading...
Amphastar Pharmaceuticals, Inc.
AMPH•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$22.37
$-0.14(-0.62%)
Amphastar Pharmaceuticals, Inc. (AMPH) Financial Performance & Income Statement Overview
Review Amphastar Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
10.62%
↑ 10.62%
Operating Income Growth
4.28%
↑ 4.28%
Net Income Growth
15.98%
↑ 15.98%
Operating Cash Flow Growth
16.28%
↑ 16.28%
Operating Margin
26.74%
↑ 26.74%
Gross Margin
50.24%
↑ 50.24%
Net Profit Margin
19.45%
↑ 19.45%
ROE
19.37%
↑ 19.37%
ROIC
13.64%
↑ 13.64%
Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement & Financial Overview
Review Amphastar Pharmaceuticals, Inc.'s (AMPH) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $186.98M | $188.82M | $182.39M | $171.84M |
| Cost of Revenue | $100.33M | $86.88M | $90.35M | $84.55M |
| Gross Profit | $86.65M | $101.94M | $92.05M | $87.29M |
| Gross Profit Ratio | $0.46 | $0.54 | $0.50 | $0.51 |
| R&D Expenses | $18.14M | $21.08M | $14.53M | $14.23M |
| SG&A Expenses | $23.36M | $23.82M | $22.30M | $25.05M |
| Operating Expenses | $41.50M | $44.89M | $36.83M | $39.28M |
| Total Costs & Expenses | $141.83M | $131.77M | $127.18M | $123.83M |
| Interest Income | $2.29M | $2.43M | $3.34M | $2.56M |
| Interest Expense | $6.42M | $6.70M | $8.61M | $8.61M |
| Depreciation & Amortization | $14.66M | $14.43M | $14.14M | $13.96M |
| EBITDA | $65.05M | $68.81M | $69.36M | $61.97M |
| EBITDA Ratio | $0.35 | $0.36 | $0.38 | $0.36 |
| Operating Income | $45.14M | $57.05M | $55.22M | $48.01M |
| Operating Income Ratio | $0.24 | $0.30 | $0.30 | $0.28 |
| Other Income/Expenses (Net) | -$1.18M | -$9.37M | -$4.97M | -$134000.00 |
| Income Before Tax | $43.96M | $47.68M | $50.24M | $47.88M |
| Income Before Tax Ratio | $0.24 | $0.25 | $0.28 | $0.28 |
| Income Tax Expense | $6.00M | $7.25M | $12.29M | $4.13M |
| Net Income | $37.96M | $40.43M | $37.95M | $43.18M |
| Net Income Ratio | $0.20 | $0.21 | $0.21 | $0.25 |
| EPS | $0.79 | $0.83 | $0.78 | $0.90 |
| Diluted EPS | $0.74 | $0.78 | $0.73 | $0.81 |
| Weighted Avg Shares Outstanding | $47.98M | $48.62M | $48.91M | $48.21M |
| Weighted Avg Shares Outstanding (Diluted) | $51.31M | $51.86M | $52.05M | $53.01M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan